Melanoma immunotherapy dominates the field
نویسندگان
چکیده
منابع مشابه
Melanoma immunotherapy
Cutaneous malignant melanoma is amongst the most aggressive cancer types, which typifies the paradox of being simultaneously highly antigenic and highly immunoevasive [1, 2]. However, various anti-melanoma immunotherapies have shown limited clinical success e.g. IL2, IFN-α2a or dendritic cells (DCs)-based vaccines [1-3]. Subsequent research showed that tumor-induced immunosuppression caused fai...
متن کاملMelanoma Genomics and Immunotherapy.
Over the last decade the molecular characterization of melanoma has progressed. Since a majority of melanoma cases arise from repeated intermittent ultra violet radiation (UVR) exposure, the role of UVR has been evaluated extensively. Recent work has identified two mechanisms in which the carcinogenesis of melanoma may result; Ultra violet radiation has been demonstrated to lead to down regulat...
متن کاملImmunotherapy of melanoma
Melanoma is considered one of the immunogenic - if not the most immunogenic - malignancies. This is based on several observations.1.Spontaneous remissions occur occasionally.2.In about 5% of melanomas no primary tumour is found. The genetic aberrations of these tumours closely resemble those of cutaneous melanomas, and therefore are suggestive of spontaneous regressions of the primary tumours.3...
متن کاملCombination Immunotherapy for Melanoma.
Advances in precisionmedicine and immunology have led tomajor paradigmshifts in thegeneral approach to treatingpatientswith metastatic cancer. This is perhaps best exemplified by malignant melanoma, an aggressive tumor characterized by alterations in definedcell signalingpathwaysandsusceptibility to recognitionby the immunesystem.Over thepast4years, therehavebeen7newdrugs approved by the US Foo...
متن کاملImmunotherapy of melanoma
The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression free survival and overall survival connected with those treatments were unprecedented and have b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Translational Medicine
سال: 2016
ISSN: 2305-5839,2305-5847
DOI: 10.21037/atm.2016.06.32